Grandfield & Dodd LLC raised its position in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 4.3% during the second quarter, Holdings Channel reports. The fund owned 1,175 shares of the biopharmaceutical company’s stock after buying an additional 48 shares during the period. Grandfield & Dodd LLC’s holdings in Regeneron Pharmaceuticals were worth $410,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of REGN. Wellington Management Group LLP increased its position in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock valued at $2,239,195,000 after buying an additional 1,426,801 shares in the last quarter. Harding Loevner LP purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $58,021,000. Renaissance Technologies LLC increased its position in shares of Regeneron Pharmaceuticals by 102.3% in the first quarter. Renaissance Technologies LLC now owns 216,962 shares of the biopharmaceutical company’s stock valued at $78,202,000 after buying an additional 109,700 shares in the last quarter. American Century Companies Inc. increased its position in shares of Regeneron Pharmaceuticals by 19.0% in the second quarter. American Century Companies Inc. now owns 602,167 shares of the biopharmaceutical company’s stock valued at $210,295,000 after buying an additional 96,340 shares in the last quarter. Finally, Temasek Holdings Private Ltd increased its position in shares of Regeneron Pharmaceuticals by 116.8% in the first quarter. Temasek Holdings Private Ltd now owns 126,351 shares of the biopharmaceutical company’s stock valued at $45,542,000 after buying an additional 68,062 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.16% during trading on Wednesday, hitting $392.60. 769,297 shares of the stock traded hands. The company’s 50 day moving average price is $403.67 and its 200 day moving average price is $391.72. Regeneron Pharmaceuticals Inc. has a 12 month low of $329.09 and a 12 month high of $592.59. The company has a market cap of $41.08 billion, a P/E ratio of 61.25 and a beta of 1.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.17. The company earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. Regeneron Pharmaceuticals’s revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.89 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals Inc. will post $11.00 EPS for the current fiscal year.
Several equities analysts have weighed in on REGN shares. Robert W. Baird reaffirmed a “neutral” rating and set a $448.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. Vetr raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $429.64 price target on the stock in a report on Monday, June 13th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $521.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, June 30th. Finally, Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $480.09.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.40% of the stock is owned by company insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.